Why is Parmax Pharma falling/rising?

As of 24-Oct, Parmax Pharma Ltd is experiencing a decline in its stock price, currently at Rs 32.31, which reflects a decrease of Rs 2.44 or 7.02%. The stock has underperformed significantly today, with a performance lagging the sector by 6.63%. It reached an intraday low of Rs 32.23, indicating a drop of 7.25%. Over the past week, the stock has seen a return of -6.18%, and it has underperformed the benchmark Sensex, which has gained 0.31%. The company's financial health is concerning, with a negative book value and weak long-term fundamentals, as evidenced by a decline in net sales by 43.96% over the last six months and a poor EBIT to interest ratio of 0.66.
In the broader market context, while the Sensex has shown a positive return of 3.05% over the past month, Parmax Pharma's performance has been negative, with a return of -0.89%. The stock's long-term performance is also troubling, with a year-to-date decline of 26.98% compared to the Sensex's gain of 7.77%. The company's weak financial metrics, including negative EBITDA and poor growth in operating profit, contribute to its risk profile, making it a strong sell. The rising investor participation, indicated by a significant increase in delivery volume, does not seem to offset the underlying financial weaknesses that are driving the stock's decline.